Seeking Alpha
View as an RSS Feed

James W. Burke  

View James W. Burke's Articles BY TICKER:
  • Adamis Pharmaceuticals: A Specialty Pharma Ready For The Next Level
    Wed, Jan. 21 ADMP 19 Comments

    Summary

    • Despite great progress on several product lines in the past year, Adamis Pharmaceuticals (ADMP) remains severely undervalued.
    • Focus on Specialty Pharma is a great move - low risk, quicker path to revenues for robust generic pipeline, including APC-5000 generic Advair, that address markets totaling over $13 billion.
    • Several near term catalysts including FDA decision due by end of March for their Epinephrine (EPI) Pre-Filled Syringe (PFS) with revenues expected 1H 2015.
    • Impressive new hires and Board Directors will help take the company to the next level.
    • Significant investment and backing by successful health care hedge fund, Sio Capital.
  • Adamis Pharmaceuticals: Two Companies For The Price Of One
    Nov. 29, 2013 ADMP 72 Comments
More on ADMP by James W. Burke